NCT02641041View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Central Nervous System (CNS) Demyelinating DiseaseMultiple Sclerosis
Interventions
BIOLOGICAL

BIIB033

single or multiple dose

OTHER

Placebo

single or multiple dose

Trial Locations (1)

LS2 9LH

Research Site, Leeds

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY